SUZANNE JAMES: Open Payments
NPI 1487187316 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$692 in 19 payments from 10 companies in 2025. Trend: 2023 $641 · 2024 $657 · 2025 $692
Food & beverage: $692
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 4 | $361 |
| Calliditas Therapeutics US Inc. | 4 | $91 |
| AKEBIA THERAPEUTICS INC | 1 | $84 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $30 |
| Novartis Pharmaceuticals Corporation | 1 | $27 |
| Vifor Pharma, Inc. | 1 | $22 |
| OPKO Pharmaceuticals, LLC | 1 | $21 |
| Travere Therapeutics, Inc. | 3 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
Products named: KRYSTEXXA, TAVNEOS, TARPEYO, Vafseo, Kerendia, Fabhalta, Veltassa, RAYALDEE.
Industry payments across MO — which companies pay providers there.
